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Abstract
PH46A is the lead of a new class of bioactive indanes with potential for the treatment of inflammatory bowel 
disease. A qualitative in vitro metabolism profile of PH46A was investigated in preclinical studies, and the rate of 
its metabolism in cryopreserved hepatocytes prepared from male Sprague Dawley rat, Beagle dog, Cynomolgus 
monkey and pooled mixed gender human was compared by LC-MS. The clearance order of PH46A was determined 
to be rat>dog>monkey>human. The species tested which exhibited the closest clearance values to the human was 
monkey. Following incubation of PH46A with cryopreserved hepatocytes, 5 metabolites were identified, including 
M1 (keto-PH46), M2 (PH46-OH, PH132), M3 (PH46-diOH), M4 (keto-glucuronide-PH46) and M5 (glucuronide 
conjugate-PH46). It was found that the human metabolites M2 and M5 were also present in rat, dog and monkey, 
while M1 was present in all species except monkey. M2 was detected in dog and monkey by LC1 conditions, but only 
in dog by LC2. Therefore, the metabolism in rat was most similar to human, in terms of the metabolites observed, 
but all putative human metabolites were present in rat and dog. We further explored the characterization of key 
metabolite M2 (PH46-OH). Identical PH46-OH was obtained via a bio-catalytic oxidation method from PH46 using 
rat liver microsomes (RLM) and the human liver P450s (Cyp2D6, Cyp 2C19 and Cyp 4A11) following screening 
of selectAZyme panels of microbial P450s, recombinant human liver P450s and different microsomes. RLM was 
used in scale up production and PH132 was isolated and characterized as 4-(((1’S,2’S)-1’,6-dihydroxy-1’,3’-dihydro-
1H,2’H-[2,2’-biinden]-2’-yl)methyl) benzoic acid via LC-MS/MS, NMR and HRMS. The site of hydroxylation on the 
biindane scaffold was unexpected. The outcomes of these studies have provided valuable information for future 
pharmacokinetic and in vivo toxicological investigations.
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Introduction
A wide range of bioactive indane based scaffolds are employed 
clinically as treatment of many disease states, including inflammatory 
[1-3], cancer [4,5] and neurological conditions [6] and also in the 
treatment of HIV [7]. Several classes of diastereoisomeric and 
enantiomeric molecules containing the indane moiety have been 
developed and characterized by our group [8-10]. Smooth muscle 
relaxation and mediator release inhibition properties have been 
demonstrated for many of these novel compounds [11-13]. In 
continuation of our work, we more recently designed and synthesized a 
series of dimeric indane compounds, with two contiguous stereogenic 
centres, one of which is a quaternary centre. Some of these compounds 
possess potent anti-inflammatory activity, in particular, a lead chiral 
molecule PH46A with S,S configurations [14-18], has been identified 
by our group and was subject to a range of preclinical studies prior to 
entering a Phase I clinical trial [19].
ADME (Absorption, distribution, metabolism, and excretion) is one 
of the major elements involved in the drug discovery and development 
process. In the last two decades, comparative in vitro metabolism 
studies of different species has been widely employed as a more cost-
effective approach to understand the animal toxicological results and 
the relevance to humans, and to characterize new drug candidates in 
the early drug discovery phase [20]. In the present study, we conducted 
an in vitro metabolism study of PH46A in cryopreserved hepatocytes 
of male Sprague Dawley rat, Beagle dog, Cynomolgus monkey and 
pooled mixed gender human in order to: (a) to identify the potential 
metabolites of PH46A and pathways of metabolism in each species; (b) 
to identify the presence/absence of unique human metabolites; (c) to 
compare the rates of metabolism of PH46A by determination of loss of 
PH46A across the species using liquid chromatography-tandem mass 
spectrometry (LC-MS/MS).
Based on the metabolism data obtained, the major metabolite 
across all species, M2 hydroxylated PH46 (PH46-OH or PH132) was 
further studied in order to support the next phase of pharmacokinetic 
investigation. The work was started with an extensive screening of 18 
recombinant human liver P450 monooxygenases, 40 microbial P450 
monooxygenases and 4 microsomes against PH46, followed by LC-MS/
MS analysis with the aim of identifying the metabolite PH132 observed 
in the metabolism study. The cytochrome P450 monooxygenases 
(P450s or Cyps) are a large family of heme protein containing enzymes 
found in animals, plants and microorganisms, which are involved 
in drug metabolism introducing a single oxygen atom derived from 
molecular oxygen into an organic molecule [21,22]. They catalyse a 
variety of reactions, such as hydroxylation of aliphatic and aromatic 
carbons, oxidation of organic nitrogen and sulphur, epoxidation and 
Baeyer-Villiger oxidation. Liver microsomes (LM) contain a cocktail of 
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different cytochromes P450, flavin-monooxygenases, carboxylesterases, 
epoxide hydrolases, UDP-glucuronosyltransferases and other drug-
metabolizing enzymes and therefore have a high success rate for any 
desired oxidation reaction [23]. In this paper, we also report the scale-
up production via the chosen biotransformation system, isolation and 
characterization of this key metabolite PH132. The potential chirality 
change of PH46 (S,S) with formation of the diastereomer to PH46, 
(R,S)-PH46, was also monitored.
Since PH46A salt dissociates in solution, the measurements of 
PH46A by LC-MS analysis throughout the two studies are related to 
the parent PH46 (free acid form). Based on structural similarities, 
compound 1 was chosen as internal standard (IS) in the metabolism 
study (Figure 1).
Materials and Methods
Chemicals
Test item PH46A, reference compounds [PH46, diastereomer 
(R,S)-PH46 & keto-PH46] and Compound 1 (IS) were obtained in-
house and used after identity/purity checking. Dulbecco’s Modified 
Eagle Medium (DMEM) was purchased from Invitrogen (UK). 
Tetrabutylammonium phosphate monobasic was purchased from 
Sigma-Aldrich (UK). 0.9% saline was obtained from Baxter (UK). All 
solvents (as anhydrous, HPLC or general process grades) were obtained 
either commercially or locally.
Biological reagents
Male Sprague Dawley rat cryopreserved hepatocytes (Lot No. 
RJW), male Beagle dog cryopreserved hepatocytes (Lot No. KLI and 
HTU), Male Cynomologus monkey cryopreserved hepatocytes (Lot 
No. YHC), and mixed gender human cryopreserved hepatocytes 
(Lot No. NQC) were obtained from Celsis, In vitro Technologies 
(MD, USA). All preparations were stored in liquid nitrogen prior to 
use. [14C]-Testosterone (Batch No. 3590023), testosterone (Batch 
No. 070M1626V) and [14C]-7-ethoxycoumarin (7-EC) (Batch No. 
RUS1277) were purchased from Perkin Elmer (UK), Sigma-Aldrich 
(UK) and Cypex (UK), respectively. All select AZymeTM enzymes 
were obtained from Almac (UK) as freeze dried cell free exacts.
Animals and husbandry
Six male Sprague Dawley rats, aged 10-12 weeks at dosing, were 
supplied by Charles River (UK) and surgically prepared with an 
indwelling femoral vein cannula. After a post-surgery recovery of ca 
7 days and prior to dose administration, a pre-study health evaluation 
was conducted on these animals and the results found to be satisfactory. 
A standard laboratory diet and mains tap water was available to the 
animals. Clinical signs were monitored throughout the study in order 
to asses any reaction to treatment.
Incubation conditions for cryopreserved hepatocytes
The primary stock solution of PH46A (4 mM) was prepared in 
distilled water, which was further diluted using distilled water to give 
the secondary stock solution (1 mM). PH46A dosing solutions were 
prepared at 40 and 10 µM in culture medium DMEM from the stock 
solutions.
A single pooled preparation from each species was used. 
Hepatocytes from each species (rat, dog, monkey and human) were 
thawed according to the suppliers’ instructions. The hepatocyte 
viability of each preparation was determined using the trypan blue 
exclusion assessment by calculating the percentage of live cells present 
[24]. Incubations were performed, in triplicate, in 12 well plates in 
an incubator with temperature of 37ºC in a humidified atmosphere 
of 95% air & 5% CO2. Test reactions contained PH46A (5 µM or 20 
µM in water) and hepatocytes (1 x 106 cells/mL) in a total volume 1 
mL of (DMEM). Each metabolic reaction was terminated after 0, 30, 
60, 90, 120 and 240 min by removing an aliquot (100 µL) from the 
appropriate well at the appropriate time point and transferring to 100 
µL of cold acidified MeOH containing IS (5 µM). After the last time-
point sampling, the remaining sample (400 µL) was mixed with cold 
acidified MeOH (400 µL) containing IS. All samples were stored at 
-20ºC until being processed. Prior to LC-MS analysis, the samples were 
thawed and the aqueous MeOH supernatants were obtained following 
centrifugation (10,000 rpm for 10 min). Control incubations were also 
performed in the absence of hepatocytes to test the stability of PH46A 
(5 µM).
For the metabolite identification phase, PH46A samples (20 µM 
in water) were incubated for 240 min only in DMEM (1 mL) with 
sampling at 0 and 240 min and terminated by an equal volume of cold 
acidified MeOH containing IS.
The metabolic competence of the cells (1 x 106 cells/mL) was 
assessed in parallel following incubations of [14C]-7-EC (10 µM in 
DMEM) and [14C]-testosterone (150 µM in ACN) in DMEM (1 mL) 
as positive control. Aliquots (100 µL) were taken and terminated 
at different time points and the samples were prepared for analysis 
as above. The remaining samples (400 µL) were mixed with the 
appropriate termination reagent.
Analytical methods validation & determination of PH46A in 
culture medium
An LC-MS/MS method for detection and quantification of PH46 in 
dosing solutions and post-incubation supernatants was developed, and 
Figure 1: Chemical structures of PH46A, PH46 and Compound 1 (internal standard).
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the following parameters (assay linearity, intra-batch assay accuracy 
and precision) were assessed.
Assay linearity: A series of calibration standards (CS) were 
prepared in DMEM containing PH46 over the target concentration 
range of 0.5-7.0 µM at a minimum of 6 concentrations, and a fixed 
concentration of IS. Calibration curves were constructed from PH46: 
IS peak area response ratios plotted against the actual concentration 
of PH46 to determine the optimum regression parameters. The 
acceptance criteria was that the calculated concentration of PH46 for 
each standard from the calibration line should be within 100 ± 15% 
of the actual amount in culture media [100 ± 20% at lower limit of 
quantification (LLOQ)]. At least 75% (and a minimum of 6) of the CS 
samples should meet the above criteria.
Intra-batch assay accuracy and precision: Replicate (n=6) quality 
control (QC) samples were prepared in DMEM containing PH46 at 
0.5, 1.2, 2.6 and 5.6 µM and a fixed concentration of IS. The samples 
were extracted and analyzed, and the concentration of each replicate 
sample was determined from the calibration curve made above. The 
acceptance criteria at each level were that the intra-batch assay accuracy 
(the mean percentage determined concentration/actual concentration) 
should be within 100 ± 15% (100 ± 20% at LLOQ) and the intra-batch 
assay precision (the coefficient of variation of the mean determined 
concentration) should be ≤ 15% at each concentration level (≤ 20% at 
LLOQ).
Chromatographic conditions: The culture medium samples were 
analyzed by LC-MS/MS and the concentration levels of PH46 in the 
samples were determined using IS. The LC-MS analysis was performed 
on Perkin Elmer series 200 and AB Sciex API 3000. Ascentis Express 
C18 column (75 x 2.1 mm, 2.7 µm) with guard column (PreFrit Filter, 
6.4 x 1.6 mm, 0.5 µm) was utilized with mobile phases: A [MeOH/acetic 
acid (AA), 100/0.2, v/v] and B (water/AA, 100/0.2, v/v). The pump 
gradient (A/B) was: 0 min (60/40), 2 min (80/20), 4 min (80/20), 4.5 
min (100/0), 4.7 min (60/40), 4.9 min (100/0) and 8.0 min (60/40) with 
flow rate of 0.3 mL/min. The column and autosampler temperatures 
were 60°C and 4ºC respectively. The injection volume was 1-20 µL (as 
required for sensitivity) with run time of 10 min (taking into account 
autosampler cycle time)]. The mass spectrometer parameters were 
Turbo Ion Spray ionisation negative mode, ion spray temperature of 
550°C, probe position of 3 mm (X) & 7 mm (Y), standard API3000 all 
nitrogen gases, settling time of 5 msec and pause time of 5 msec.
Calculations & run acceptability: Integration of PH46 and IS 
peaks was done by a smoothing factor of 2 and the peak area ratio 
of PH46:IS for each CS, QC and test samples were calculated. A 
calibration curve was constructed by plotting the peak area ratio of the 
calibrations standards vs. the concentration of each test item in matrix 
and determine the linear regression parameters of the curve, using a 
weighting factor of 1/x2 (1/concentration2). The concentration of PH46 
in QC samples and test samples was determined by interpolation of the 
peak area ratios from the calibration curve. At least 75% of CS samples 
must back-calculate to within 100 ± 15% of the actual concentrations 
(100 ± 20% at the lower limit of quantification). At least 66% of 
QC samples must be within 100 ± 15% of the actual concentration, 
including at least one at each level.
Each batch contained double blank sample (absence of both PH46A 
and IS), single blank sample (absence of PH46A and presence of IS), CS 
samples, QC samples and test samples. The CS samples were prepared 
at 0.5, 1.3, 1.8, 2.3, 2.7, 3.2, 3.7, 4.5, 5.0, 6.2 and 7.0 µM, which were 
injected at the start of each batch. Duplicate LLOQ (0.5 µM) and upper 
limit of quantification (ULOQ) (7.0 µM) was also made to minimize 
the risk of not achieving a valid standards at LLOQ or ULOQ levels. 
Only one of the CS samples, at each concentration level, was employed 
in the assay calibration line. QC samples were prepared in duplicate at 
least at 1.2, 2.6 and 5.6 µM. For the analysis of test samples groups of 
one at each of low, medium and high concentrations of the QC samples 
were analyzed after the calibration line and after study samples. Where 
QC samples are prepared in triplicate, additional groups of QC samples 
should be interspersed within the test samples. Study samples were run 
bracketed by groups of QC samples. The test samples were analyzed 
from low to high concentrations. Under normal assay conditions two 
reconstitution solvent samples MeOH/water/AA (50/50/0.2, v/v/v) 
samples were used after the top standard and high QC samples to avoid 
significant carryover.
HPLC analysis of supernatants from [14C]-7-EC & [14C]-
testosterone incubations
[14C]-7-EC, [14C]-Testosterone and their corresponding metabolites 
present in the post-incubation supernatants were resolved by HPLC 
analysis performed on Waters 2695 separations module with Waters 
486 Tunable absorbance detectors and Perkin Elmer RadiomaticTMFlo-
one®\Beta Scintillation Analyser (Model 150TR). For [14C]-7-EC 
incubation, Hypersil BDS C8 column (250 x 4.6 mm, 5 µm) was used 
with mobile phases: A [tetrabutylammonium phosphate monobasic 
in water (5 mM)/AA, 100/1, v/v] and B (ACN/AA, 100/1, v/v). The 
pump gradient (A/B) was: 0 min (94/6), 10 min (49/51), 20 min 
(49/51), 25 min (94/6) and 35 min (94/6) with flow rate of 1 mL/min. 
The column and auto sampler temperatures were ambient and 10°C, 
respectively. The injection volume was 0.1 mL with run time of 35 min. 
UV wavelength 320 nm was used with data captured by Labsystems 
Atlas 2002 R1. For [14C]-testosterone incubations, Novapak C18 
column (150 x 3.9 mm, 4 µm) and pre-Column Novapak C18 (20 x 
3.9 mm, 4 µm) were used with mobile phases: A (water), B (MeOH) 
and C (ACN). The pump gradient (A/B/C) was: 0 min (75/25/0), 40 
min (30/64/6), 45 min (75/25/0) and 55 min (75/25/0), with flow rate 
of 1 mL/min. The column and autosampler temperatures were 50°C 
and 10°C, respectively. The injection volume was 0.1 mL with run time 
of 55 min. UV wavelength of 240 nm was used with data captured by 
Labsystems Atlas 2002 R1.
Calculation of intrinsic clearance
Intrinsic clearance values were calculated using the following 
equation. The physiological parameters (no. of hepatocytes per g of 
liver & g of liver per kg of bodyweight) used were: 120 x 106 & 40 for 
Rat [25], 240 x 106 [26] & 32 [27] for dog, 135 x 106 & 25 for monkey 
[28] and 120 x 106 & 26 for human [25].
1/2
0.693 mLincubationIntrinsicClearance = ×
T (min) no.of hepatocytes
no.of hepatocytes g of liver weight× ×
g of liver weight kg of body weight
invitro
Where in vitro T1/2 is estimated using the gradient (k) of the line of 
the logarithmic mean % parent compound remaining against, and the 
equation: in vitro T1/2 = 0.693/-k.
Analytical method for metabolite identification
The metabolite profiling investigation following incubation was 
performed by LC-MS/MS analysis using Shimadzu LCMS-IT-TOF 
mass spectrometer and Shimadzu Prominence HPLC with pumps (LC-
20ADXR), degasser (DGU-20A3), autosampler (SIL-20ACXR), column 
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oven (CTO-20ACXR), DAD (SPDM20AXR) and communications 
module (CBM-20AXR).
LC conditions 1 (LC1): Agilent EC-C18 column (50 × 2.1 mm, 
1.7 µm) was used with mobile phases: A (water/AA, 100/0.2, v/v) and 
B (MeOH/AA, 100/0.2, v/v). The pump gradient (A/B) was: 0 min 
(70/30); 11 min (0/100); 12 min (0/100); 13 min (70/30) and 15 min 
(70/30) with flow rate of 0.3 mL/min. The column and autosampler 
temperatures were 60°C and 4°C, respectively with diode array detector 
(DAD) range of 190-800 nm.
LC conditions 2 (LC2): Kinetix PFP column (50 × 2.1 mm, 1.7 µm) 
was used with mobile phases: A (water/AA, 100/0.2, v/v) and B (MeOH/
AA, 100/0.2, v/v). The pump gradient (A/B) was: 0 min (90/10); 11 min 
(0/100); 12 min (0/100); 13 min (90/10) and 15 min (90/10) with flow 
rate of 0.3 mL/min. The column and autosampler temperatures were 
60°C and 4°C with DAD range of 190-800 nm.
MS conditions: Electrospray ionisation (ESI) was selected 
with both curved desolvation line and block temperatures at 230°C. 
The nebulising gas (N2) flow was 1.5 L/min with collision-induced 
dissociation gas of Argon and drying gas on. The data acquisition in 
both positive and negative mode was achieved using automatic gain 
control (ASC 10e6) and the Q (low mass cut-off) value was 0.251 (45 
kHz) with precursor ion isolation of 3 amu.
Accurate mass measurement was used to differentiate between 
potential metabolites with the same nominal mass. The accurate 
mass error (ppm) was calculated from a comparison of the measured 
mass with the theoretical mass for a suggested assignment. A low 
accurate mass error (< 5 ppm) supports the assignment. Conversely 
a large accurate mass error would refute the assignment. Metabolite 
screening software (Met ID Solutions version 1.2) was also used to aid 
the identification of potential metabolites. Analysis of T0 sample was 
used to subtract background matrix for each species. A media control 
sample was used to indicate any non-metabolic changes to PH46. The 
output of the software screening was reviewed and possible metabolites 
investigated further manually.
Screening of enzymes & microsomes against PH46 & LC-MS 
detection
Almac’s selectAZyme panels of 18 recombinant human liver P450 
monooxygenases, 40 recombinant microbial P450 monooxygenases 
(self-sufficient cytochrome P450 enzymes were heterologously 
expressed in E. coli) and 4 different microsomes were screened against 
PH46 using a glucose dehydrogenase based cofactor regeneration 
system. Reactions were analyzed after 4 h and overnight reaction time 
by newly developed LC-MS method, LC3, in both positive & negative 
modes, and the tentative metabolite hits were further analyzed via 
MS/MS experiments. The details of the screening procedure and the 
corresponding tentative metabolite screening results are provided in 
Supplementary Table S1.
LC conditions 3 (LC3) (for screening purpose only): Luna C18 
(50 x 2 mm, 3 µm) was used with mobile phases: A (water/AA, 100/0.1, 
v/v) and B (ACN/AA, 100/0.1, v/v). The pump gradient (A/B) was: 0 
min (70/30), 5 min (35/65), 5.10 min (0/100), 7 min (0/100), 7.10 min 
(70/30) and 10 min (70/30) with flow rate of 1 mL/min. The column 
temperature was ambient temperature.
LC conditions 4 (LC4): It was further developed for all further 
analysis throughout the biotranformation study, due to the most 
accurate match of the relative retention times of the metabolites 
observed in the metabolism study. Kinetix C18 (50 x 4.6 mm, 2.6 µm) 
was used with mobile phase: A (water/AA, 100/0.2, v/v) and B (MeOH/
AA, 100/0.2, v/v). The pump gradient (A/B) was 0 min (70/30), 11 min 
(0/100), 12 min (0/100), 13 min (70/30) and 15 min (70/30) with flow 
rate of 0.5 mL/min. The column temperature was 60°C.
MS conditions: AB Sciex QQQ 365; Scan type: Q1 MS; polarity: 
positive/negative; ion source: turbo spray; mass range: 100-700; NEB: 
8; CUR: 8; IS: 4200; TEM: 300; DP: 46; FP: 180; EP: 9.
Scale-up production of PH132 via selected bio-oxidation 
system and characterization methods
The procedure outlined below was performed on 500 mL scale 
and total of 12 x 500 mL reactions were conducted. KH2PO4 buffer 
(100 mM, 500 mL) were prepared containing MgCl2 (5 mM), with 
pH adjustment to 7.4 using KOH solution. 437.5 mL of such buffer 
was then transferred into 2 L Erlenmeyer flask, followed by additions 
of Glucose (3.6 g) and GDH (2 g). The resulting mixture was gently 
stirred until complete dissolution, followed by the addition of 1 mL 
of PH46 stock solution (262 mM in DMSO) and 12.5 mL of RLM. 
The reaction was started with the addition of nicotinamide adenine 
dinucleotide phosphate Na-salt solution (40 mM, 50 mL) and was left 
shaken overnight at 37ºC at 200 rpm. The flasks were “closed” with 
a punctured tin foil to allow for oxygen transfer. ACN (125 mL) was 
added to quench each reaction, and the resulting solids (from proteins 
precipitation) were removed by centrifugation at 8000 rpm for 10 min. 
The residual solution was analyzed by LC-MS method using LC4 to 
determine conversions and subsequently prepared for sold phase 
extraction (SPE) and prep-HPLC purification.
SPE: A 60 mL Strata-X (33 u, polymeric reverse phase) tube was 
initially washed with MeOH (150 mL) and equilibrated with water (300 
mL), followed by sample loading (1500 mL of three reactions for the 
column). The flow through and the water washes were collected and 
analyzed for the desired product by HPLC. After sample loading, the 
tube was subsequently washed with water (300 mL). Before the tube 
became dry, it was wetted with MeOH. MeOH was incubated on the 
column for 5 min without flow. The material was subsequently eluted 
with MeOH (150 mL) at minimum flow. More MeOH was used for 
the complete elution, which was checked by HPLC. All fractions were 
combined and diluted to a 20% MeOH solution with water for the next 
step, prep-HPLC purification.
Prep-HPLC purification was performed on Luna semi prep-HPLC 
column (250 x 30 mm, 10 µm) with 750 mL of sample (containing 
300 mg of crude material after dilution) applied to the column via 
an external pump operating at 9 mL/min. The isocratic mobile phase 
system, ACN/Water/AA (40/60/0.1, v/v/v), was used with flow rate 
of 42.5 mL/min for each injection (600 mg of crude were created in 
total 2 injections). The total run-time was 70 min. The purity of the 
fractions was then tested by LC4 and the fractions containing PH132 
with purities >95% were pooled and concentrated to dryness by vacuo 
at 37ºC. ACN was used to azeotroph any residual water. The fractions 
with less purity were combined and purified further.
NMR spectra were recorded on Bruker DPX-600 and Bruker DPX-
400 instruments operating at 400.1 MHz and 600.1 MHz for 1H NMR; 
100.6 MHz and 150.9 MHz for 13C-NMR and calibrated using residual 
undertreated solvent as an internal reference (CHCl3@ δ 7.26 ppm 1H 
NMR, δ=77.16 13C NMR; DMSO-d6@ δ=5.32 ppm 1H NMR, δ=39.51 
ppm 13C NMR). The following abbreviations were used to explain 
1H NMR multiplicities: s=singlet, d=doublet, t=triplet, m=multiplet, 
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br=broad. NMR spectra were analyzed with Bruker Toppsin 3.5pl7 
software. High-resolution mass spectra (HRMS) were measured on 
a Micromass LCT electrospray TOF instrument with a WATERS 
2690 autosampler and methanol as carrier solvent. Data analysis was 
performed using MassKynx software.
Results and Discussion
Assay linearity, intra-batch assay accuracy and precision
It was found that regression analysis of the peak area ratios of 
PH46:IS against the amount of PH46 had demonstrated good linearity 
in culture medium over the range 0.5-7 µM with a 1/x2 linear weighting. 
The determined concentrations for these standards (0.50, 1.25, 1.75, 
2.25, 2.69, 3.23, 3.74, 4.49, 4.99, 6.24 and 6.98 µM) met the acceptance 
criteria. The intra-batch accuracy and precision of the assay for PH46A 
in DMEM met the acceptance criteria for each concentration level 
(0.50, 1.24, 2.64 and 5.60 µM) with replicate (n=6). The actual results 
are giving in Supplementary Tables S2 and S3.
Incubation of PH46A (5 µM) with cryopreserved hepatocytes
The hepatocyte viability assessment for all species was above 75% 
acceptance criterion with the viability values of 84.3% (male rat), 
80.7% (male dog), 78.0% (male monkey), 76.4% (mixed gender pooled 
human). Incubation of PH46A at 5 µM with cryopreserved hepatocytes 
resulted in partial loss of PH46 in all four species at all-time points, 
except T=0 min, over the time course of the incubation of 240 min. 
This loss was not observed significantly during incubation of PH46A 
with DMEM, indicating that PH46 appeared to be stable over the time 
course under incubation conditions; however small portion (~10%) of 
PH46 loss was seen after 30 min of incubation in DEME, which was 
considered to be due to weak interaction between PH46 and amino 
acids present in DEME media.
The concentration of PH46 remaining at 240 min was found to 
be below LLOQ (0.5 µM) following incubation with rat and human 
cryopreserved hepatocytes. The percentage of PH46 remaining at 
240 min was 10.8% and 12.4% following incubation with dog and 
monkey hepatocytes, respectively. The results are presented in Table 
1. The natural log (ln) of the percentage of PH46 remaining was also 
calculated. The in vitro intrinsic clearance values following incubation 
at 5 µM of PH46A (mL/min/kg body weight) were also determined to 
be 93.1 (rat), 72.2 (dog), 30.0 (monkey) and 24.4 (human). The order of 
clearance for the species was rat>dog>monkey>human.
Incubation of [14C]-7-EC and [14C]-testosterone with cryopreserved 
hepatocytes
Incubations of cryopreserved hepatocytes with [14C]-7-EC and 
[14C]-testosterone resulted in partial or complete disappearance of 
parent compounds over 240 min incubation periods. In the case of 
[14C]-7-EC, 3 of the metabolites formed were identified in all species 
against authentic standards: 7-hydroxycoumarin (7-HC) (phase I), 
7-HC glucuronide and 7-HC sulphate (phase II). For [14C]-testosterone, 
the major metabolite 6β-hydroxytestosterone was identified against 
an authentic standard in all species. The above data indicates that 
all hepatocytes were intact and were suitable for the assessment of 
metabolism of PH46A.
Metabolite profiling of PH46A in rat, dog, monkey and 
human hepatocytes
Reference standard PH46 was analyzed first. Accurate mass 
measurement of the deprotonated molecular ion (m/z 381 [M-H]-) 
with retention time (RT) 7.9 min confirmed the formula C26H22O3. The 
corresponding protonated ion was not observed, which was believed 
to be due to loss of water in the mass spectrometer source resulting 
in the presence of the ion with m/z 365 [M+H]+. Two potential routes 
were considered as two potential fragment ion structures were possible 
for the fragment ions with m/z 261 & 245. Fragmentation resulting 
in the loss of the indanol moiety was supported by accurate mass 
measurement. A fragmentation pathway was postulated based on 
analysis of the free acid form (PH46) of PH46A (Figure 2).
The representative chromatograms and mass spectra are given 
in Supplementary Figure S1. Comparison of the fragment ions 
observed for PH46 and postulated metabolites was used to support 
metabolite identification. During the metabolite profiling study, PH46 
and metabolites (M1-M5) were detected in the same species by LC-
MS analysis at 240 min under both LC1 and LC2 conditions, with 
the exception of M4 (Figure 3). A summary of metabolite detection 
by LC1 for each species and the corresponding UV chromatograms 
Incubation 
time (min)
125  
Rat   
100  Dog 
 
  Monkey 
75 
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50 
 Media Only 
  
   
25   
0   
0 100 200 
 Incubation Time (min) 
Mean % of PH46 remaining ± standard deviation
5  
Rat   
  Dog 
  
4  Monkey  
Human   
  Media Only 
3     
   
2   
0 100 200 
 Incubation Time (min) 
ln Mean % of PH46A remaining
Rat Dog Monkey Human DMEM Only Rat Dog Monkey Human DMEM Only
0 100 ± 6.55 100 ± 5.69 100 ± 6.89 100 ± 2.99 100 ± 3.81 4.61 4.61 4.61 4.61 4.61
30 59.3 ± 0.32 77.9 ± 1.72 84.7 ± 1.62 83.8 ± 3.72 88.9 ± 1.19 4.08 4.36 4.44 4.43 4.49
60 32.3 ± 0.94 56.1 ± 0.69 67.3 ± 4.82 66.6 ± 2.25 90.6 ± 1.18 3.48 4.03 4.21 4.20 4.51
90 18.5 ± 1.59 40.5 ± 1.81 52.7 ± 0.78 56.3 ± 7.45 90.0 ± 0.41 2.92 3.70 3.96 4.03 4.50
120 9.77* 29.7 ± 1.34 38.4 ± 2.23 37.6 ± 1.65 90.9 ± 1.07 2.28* 3.39 3.65 3.63 4.51
240 <LLOQ 10.8 ± 0.58 12.4 ± 1.36 <LLOQ 94.74 ± 5.26 <LLOQ 2.38 2.52 <LLOQ 4.55
Table 1: Percentage (left) and ln percentage (right) of PH46 remaining following incubation of PH46A with cryopreserved hepatocytes. <LLOQ:below the lower limit of 
quantification (0.5 µM). ln: natural log. Values obtained from 3 individual determinations with the exception of * which was determined from an individual determination, as 
the other two values were below the LLOQ.
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as representative are presented in Table 2 and Figure 4. The details 
of each metabolite’s identification are described below and the 
related chromatograms and spectra of each metabolite are given in 
Supplementary Figures S1-S5.
PH46: The deprotonated ion m/z 381 ([M-H]-) was observed at RT 
of ca. 8.15 min (LC1) which was consistent with PH46. Accurate mass 
measurement confirmed the molecular formula as C26H22O3, and the 
product ions m/z 261, 245, 135 and 115 ([M-H]-) observed following 
fragmentation was consistent with PH46. A response for the positive 
ion m/z 365 ([M+H]+), formed by loss of water in the mass spectrometer 
source was also observed. This in-source fragmentation of the positive 
molecular ion was also consistent with the PH46 reference standard 
analysis and therefore was deemed to reinforce the identification of 
PH46 in hepatocyte incubates.
M1 (keto-PH46) with m/z 379 (RT ca. 8.7 min): The ion m/z 
379 ([M-H]-) were observed for each species except monkey, which 
were postulated to correspond to keto-PH46 (C26H20O3) with RT of 
8.7 min in the extracted ion chromatogram (EIC), and confirmation 
was obtained from accurate mass measurement. Fragmentation of the 
deprotonated molecular ion resulted in the product ions m/z 244 & 135 
which was consistent with the fragmentation of the parent PH46 and 
thus supports the identification. A representative example is shown in 
Supplementary Figure S2.
M2 (PH46-OH, PH132) with m/z 397 (RT ca. 6.5 min): The 
ion m/z 397 ([M-H]-) were observed for each species. Accurate mass 
measurement confirmed the formula C26H22O4 corresponding to 
PH132. Fragmentation of the deprotonated molecular ion resulted in 
the product ions m/z 261 and 135. These fragment ions were consistent 
with PH46 fragmentation and suggested hydroxylation may occur 
on the indanol moiety (Supplementary Figures S3-S9). The spectra 
observed at 6.5 and 6.8 min were of low intensity which may be due 
to suppression by other ions such as m/z 557 which was not related to 
PH46 metabolism based on accurate mass observed.
M3 (PH46-diOH) with m/z 413 (RT ca. 6.3-7.5 min): The ion m/z 
413 ([M-H]-) were observed in rat and the presence of peaks with RTs 
ca. 6.3-7.5 min in the EIC using LC2 indicated several isomers could 
be possible (Figure S5). Accurate mass measurement of the molecular 
ion confirmed the formula C26H22O5 corresponding to PH46-diOH. 
Fragmentation of the deprotonated molecular ion resulted in the 
product ions m/z 395 & 377.
These fragments suggested the consecutive loss of two molecules of 
water from PH46-diOH and it was postulated that hydroxylation may 
occur on adjacent positions within a ring moiety. A structure for the 
fragment ion m/z 395 has been suggested but a mechanism by which 
a second loss of water from the ion m/z 395 to yield ion m/z 377 was 
not clear. It is envisaged that dihydroxylation could be possible on any 
of the 3 ring moieties, but it was not possible to confirm this from the 
product ions obtained by current study.
M4 (keto-glucuronide-PH46) with m/z 555 (RTs ca. 8.0-8.2 
min): The ion m/z 555 ([M-H]-) were observed for monkey and dog 
at 240 min by LC1 and for dog only by LC2, which were postulated to 
correspond to a ketone glucuronide of PH46. The presence of several 
peaks with RTs ca. 8.0-8.2 min in the EIC by LC2 indicates that several 
isomers (as with the glucuronide) are possible (Figure S6). Accurate 
mass measurement confirmed the formula C32H28O9. The deprotonated 
molecular ion fragmentation resulted in the product ion m/z 379 
which were in turn fragmented resulting in product ions m/z 245 & 
135, consistent with those formed following PH46 fragmentation. The 
spectra observed ca 8.0-8.2 min were of low intensity which may be due 
to suppression by other ions such as m/z 521.
Figure 2: Postulated fragmentation pathway of PH46 reference standard by 
LC-MS analysis.
Figure 3: Molecular structures of five metabolites (M1-M5) of PH46 detected.
Species RT (min) m/z ([M-H]-) Postulated ID
Rat
6.445 397 M2
6.605 397 M2
8.032 381 PH46
8.556 379 M1
Dog
6.439 397 M2
6.608 557 M5
6.874 N/A N/A
7.326 555 M4
8.033 381 PH46
8.556 379 M1
Monkey
6.434 397 M2
6.605 557 M5
8.032 381 PH46
Human
6.445 397 M2
6.608/6.875 557 M5
8.032 381 PH46
8.556 379 M1
Table 2: Summary of metabolite detected by LC-MS/MS (240 min, LC1) for each 
species (M1:keto-PH46; M2: PH46-OH (PH132); M4: keto-glucuronide-PH46; M5: 
glucuronide-PH46).
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M5 (glucuronide conjugate-PH46) with m/z 557 (RT ca. 7.3-7.7 
min): The ion m/z 557 ([M-H]-) were observed for each species using 
both LC1 & LC2. An example of rat sample analysis via LC2 is given 
in Figure S7. These were postulated to correspond to glucuronide-
PH46 and several unresolved peaks with RT ca. 7.3-7.7 min in the EIC 
indicated that several isomers were possible (Figure S8). These could 
be postulated to be the result of acyl migration and the analysis using 
LC1 afforded better resolution of the possible isomers (Figure S9). 
Accurate mass confirmed molecular formula C32H30O9 corresponding 
to glucuronide-PH46. Fragmentation of the deprotonated molecular 
ion resulted in ion m/z 381, which was further fragmented forming 
product ions consistent with those formed following fragmentation of 
PH46.
The results showed that PH46 was observed in all samples at 0 and 
240 min and PH46A with hepatocytes resulted in the formations of 
5 metabolites among various species: M1 (keto-PH46), M2 (PH46-
OH, PH132), M3 (PH46-diOH), M4 (keto-glucuronide-PH46), M5 
(glucuronide conjugate-PH46). LC-MS experiments via both LC1 and 
LC2 conditions provided the prominent and informative product ions 
for structural elucidation Table 3 and a summary of the qualitative 
metabolite formation following incubation is shown in Table 4. The 
postulated fragmentation pathways of all 5 metabolites are given in 
Figure 5.
The metabolic pathways shared similarities in all species tested. 
Two common metabolic routes to all species appeared to be phase I 
hydroxylation and phase II glucuronidation resulting in the formations 
of M2 and M5, respectively. In addition, oxidative transformation as 
minor metabolic pathway was detected in all species except monkey 
samples due to absence of M1 under both LC1 and LC2 conditions. 
M3 as unique metabolite was witnessed in rat hepatocyte sample. 
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Figure 4: UV chromatograms (240 min, LC1) of LC-MS analysis for each species: rat (a), dog (b), monkey (c) and human (d).
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Component
RT (min) Nominal mass
Formula Characteristic ions
LC1/LC2
(Accurate mass)
[M-H]-
PH46 8.0 / 8.7 381 (381.1496) C26H22O3 261, 245, 135, 115
M1 8.7/ 9.2 379 (379.1339) C26H20O3 244, 135
M2 6.5/ 7.7 397 (397.1445) C26H22O4 261, 135
M3 3.8/ 6.3 413 (413.1394) C26H22O5 395, 377
M4 7.4/ 8.0 555 (555.1661) C32H28O9 379, 245, 135
M5 6.7/ 7.5 557 (557.1817) C32H30O9 381, 261, 245
Table 3: Product ions of PH46 and its 5 metabolites observed by LC-MS. M1: keto-PH46; M2: PH46-OH; M3: PH46-diOH; M4: keto-glucuronide-PH46; M5: glucuronide 
conjugate-PH46.
LC conditions Species PH46 M1 M2 M3 M4 M5
LC1
PH46 reference √ - - - - -
Rat √ √ √ √ - √
Dog √ √ √ - √ √
Monkey √ - √ - √ √
Human √ √ √ - - √
DMEM √ - - - - -
LC2
PH46 reference √ - - - - -
Rat √ √ √ √ - √
Dog √ √ √ - √ √
Monkey √ - √ - - √
Human √ √ √ - - √
DMEM √ - - - - -
Table 4: Summary of metabolite detection by LC-MS (240 min, LC1 & LC2) for all species.
√ Successfully detected. 
-  Not detected
Figure 5: Postulated fragmentation pathways of observed metabolites M1 (blue), M2 (black), M3 (green), M4 (purple) and M5 (red).
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Furthermore, the observation of M4 in dog and monkey samples 
suggested that PH46 was susceptible to oxidation at hydroxyl 
functionality, followed by glucuronidation conjugation reaction. 
However, M4 was not detected in monkey samples under LC2. It is 
important to note that no major human-specific metabolite was 
found. Due to the qualitative nature of the current work, it was not 
possible to provide quantification of the metabolites detected. The 
relative quantification between T0 and the T240 in each species may be 
inferred from the UV chromatograms; however, the comparison of UV 
chromatograms was required with caution.
Recombinant enzymes and microsomes screening
The proposed route to the generation of the desired PH132 
metabolite by biocatalysis involved initial screening using microbial 
P450s, recombinant human liver P450s and microsomes, tentative 
hits were observed after 4 h with rat liver microsomes (RLM) (~7% 
conversion) and human Cyp-3 (Cyp2D6, ~11% conversion), human 
Cyp-4 (Cyp2C19, ~11% conversion) and human Cyp-13 (Cyp4A11, 
~25% conversion). The result of the RLM reaction after 24 h incubation 
via LC3 showed that the hydroxyl group in PH46 was unstable under 
the positive mode, with observations of 365 amu (PH46-H2O) and 381 
amu (PH132-H2O) only (see chromatograms and spectra in Figure 6).
During the MS/MS experiments of the RLM sample against 
reference PH46, fragmentation patterns in both negative mode (135 
& 261 amu) and positive mode (131, 135, 246 & 249 amu) were 
comparable to those of PH46. The presence of 397 amu under negative 
mode confirmed the existence of the metabolite PH132; while the 
detection of 381 amu from the positive mode allowed significant insight 
into the structure of PH132, which suggested that the OH-group was 
attached onto the aromatic ring within the indene system (Figure 7). 
The corresponding chromatograms of the MS/MS experiments are 
shown in Supplementary Figures S10 and S11.
The identity of PH132 generated from the biotransformation 
screening was confirmed by a series of spiking experiments using LC4 
method, including spiking against the in vitro metabolism hepatocyte 
samples [rat or human hepatocytes (6 µg/ml) spiking with the bio 
catalytic screening reaction samples being 10 fold more concentrated], 
and cross spiking between the RLM and Cyps screening samples (same 
concentration). The EIC at 397 amu was used for clear comparison. 
The details of these spiking experiments results are provided in 
Supplementary Figures S12-S17.
Two other tentative metabolites were also observed, PH46-OH’ in 
one human Cyp-9 (2C9) sample and PH46-diOH in various microbial 
Cyp samples (Figure 6). In the incubation with Cyp 9 for 24 h, two 
peaks with the desired mass of 381 amu (PH132-H2O) were observed 
in the positive mode LC3. The MS/MS experiment revealed that the 
fragmentation pattern of both peaks was very similar, which suggested 
one could be the desired metabolite PH132 and one being a different 
isomer, PH46-OH’. However, due to the low concentration, no further 
structural conclusion of PH46-OH’was made. The LC-MS and MS/
MS results are given in Supplementary Figures S18 and S19. In some 
Cyp samples, incubated with microbial P450 enzymes, the peak with 
415 amu was observed, being possibly metabolite M3 (PH46-diOH). 
However, upon further investigation of MS/MS experiments, the 
fragmentation pattern of the peak with 415 amu had no similarity with 
that of either PH46 or PH132. It is possible that this observed peak had 
not originated from PH46, thus not being a metabolite. The relevant 
chromatograms are given in Supplementary Figures S20 and S21.
Structure elucidation of metabolite PH132 by NMR & HRMS
PH132 was isolated with purity of 95% Rat liver microsomes bio 
catalytic systems were used in the subsequent scale-up production 
of PH132 metabolite. Upon reaction work up and purification, The 
combined samples (from 12 reactions) were dried for 2 d on a high 
a Peak 1 
Peak 2 
Peak 1 b
Peak 2 
Figure 6: LC-MS total wave chromatogram (TWC, a) and total ion chromatogram (TIC, b) of PH46 incubated with rat liver microsomes (RLM) for 24 hours, with 
mass spectra (under positive mode) of peaks 1 and 2.
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vacuum manifold and 64 mg of PH132 (62% yield) was obtained 
with purity of 95%, as white powder. PH132 was characterized and 
its chemical structure was confirmed by NMR experiments using 
PH46 as reference for comparison (Figure 8). The molecular mass 
and absolute configurations were also monitored by HRMS and 
polarimetry. Representative NMR spectra are given below (Figures 
9-13). The detailed NMR spectra and chromatograms are provided in 
Supplementary Figures S22-S28.
1H and 13C NMR data of PH46 were in agreement with the data we 
previously reported (Figures 9 and 10) [17]. The 1H NMR spectrum 
of PH132 (Figure 11) shared similar spectral pattern as that of PH46. 
Structural assignments of PH132 were achieved with combinations of 
1D (1H, 13C, DEPTs & NOESY) and 2D (1H-1H COSY, HSQC, HMBC 
& ROESY) NMR experiments.
The HSQC NMR spectrum of PH46 (blue) overlaying with the 
HSQC (red) and 1H (green) NMR spectra of PH132 allowed the 
correlation of the assignments of most proton signals detected in the 
aromatic region in the 1H spectrum of PH132 (Figure 12). The key 
feature in this analytical technique was the observation of the signal 
of the aromatic proton H16 of PH132 at 6.90 ppm being a broad 
doublet. The 1H-1H COSY spectrum of PH132 confirmed the existence 
of the aromatic protons H18, H19, H21, H22, H24 and H25 from the 
correlations observed in Figure 13a.
The position of the double bond on the indene ring was further 
identified by ROSEY NMR experiments via w-coupling (NOE 
correlation) between the alkenic proton H19 at 6.90 ppm being a 
board doublet and the aromatic proton H15 at 7.02 ppm being a 
multiplet (Figure 13b). As a result, the position of the hydroxyl group 
of PH132 produced was determined to be at the C17 position. The 
chirality of PH132 was also measured by optical rotation. A negative 
value was obtained, which is consistent with PH46. Therefore, PH132 
is chemically named as 4-(((1’S,2’S)-1’,6-dihydroxy-1’,3’-dihydro-
1H,2’H-[2,2’-biinden]-2’-yl)methyl)benzoic acid. The details of 
characterization of PH132 are: 1H NMR (600.1 MHz, DMSO-d6) δ 
2.70 (1H, d, J=13.31 Hz, CH2), 32.91 (1H, d, J=15.70 Hz, CH2), 2.94 
(1H, d, J=15.70 Hz, CH2), 3.16 (1H, d, J=13.31 Hz, CH2), 3.36 (1H, d, 
J=22.80 Hz, CH2), 3.47 (1H, d, J=22.80 Hz, CH2), 5.02 (1H, d, J=6.90 
Hz, CHOH), 5.75 (1H, d, J=7.66 Hz, OH), 6.27 (1H, s, CH=C), 6.58 
a b
 d  c
Figure 7: LC-MS/MS experiment results of PH46 (a) and PH132 (b) in negative mode, PH46 (c) and PH132 (d) in positive mode.
Figure 8: Chemical structures of PH46 (left) and desired metabolite PH132 
(right).
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(1H, dt, J1=2.74 Hz, J2=8.23 Hz, Ar-H), 6.85-7.36 (8H, 4 x m, Ar-H), 
7.69 (2H, d, J=8.28 Hz, Ar-H); 13C NMR (150.9 MHz, DMSO-d6) δ 38.1 
(CH2), 38.3 (CH2), 39.2 (CH2), 55.5 (quat. C), 81.0 (CHOH), 111.4 (tert. 
C), 112.9 (tert. C), 120.4 (tert. C), 124.1 (quat. C), 124.2 (tert. C), 124.4 
(tert. C), 126.2 (tert. C), 126.7 (CH=C), 127.5 (tert. C), 128.3 (quat. 
C), 2 x 128.5 (2 x tert. C), 2 x 129.9 (2 x tert. C), 135.8 (quat. C), 140.4 
(quat. C), 144.6 (quat. C), 145.1 (quat. C), 149.9 (quat. C), 154.7 (quat. 
C), 167.5 (COOH). HRMS (ESI): m/z calculated for C26H21O4 (M-H)+, 
397.1440; found 397.1436; [α]D22 = -96.9° (12.8 mg/1 mL, MeOH).
Conclusion
In summary, the in vitro metabolism study of the clinical candidate 
PH46A were studied by our group. Five metabolites were identified, 
including M1 (keto-PH46), M2 (PH46-OH or PH132), M3 (PH46-
diOH), M4 (keto-glucuronide-PH46) and M5 (glucuronide conjugate-
PH46) across species tested; while PH46 was confirmed in all samples at 
0 and 240 min incubation time. Overall, all putative human metabolites 
were present in rat and dog. Metabolism in rat was most similar to 
human in terms of the metabolites observed. The order of clearance 
of PH46 was determined to be rat>dog>monkey>human. The species 
which exhibited the closest clearance values to the human was monkey. 
The rat produced the highest clearance of PH46 of all the species. 
Further studies will be carried out to investigate the stereochemistry 
of each metabolite to determine whether different stereoisomers of the 
metabolites were present following incubation.
We further developed an efficient biocatalytic method to generate 
one of the key metabolites, PH132, following an extensive screening 
of the selectAZyme panel of enzymes. Recombinant human liver 
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Figure 9: 1H NMR spectrum of PH46 with atom assignments.
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Figure 10: 13C NMR spectrum of PH46 with atom assignments.
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Cyps and RLM were identified as being capable of producing desired 
PH132, which was confirmed by a series of spiking experiments. RLM 
were selected for use for the subsequent scale-up reaction, and the full 
chemical structure characterisation of isolated and purified PH132 was 
confirmed by LC-MS/MS and a complete series of NMR experiments. It 
was revealed that the position of the OH moiety was at the C17 position 
locating on the aromatic ring of the indene system. The results obtained 
from the work are important for understanding the metabolism of 
PH46A in human and provide important information that may act as a 
reference for the next stage of pharmacokinetics, in vivo toxicology and 
clinical pharmacology investigations.
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Figure 11: 1H NMR spectrum of PH132.
Figure 12: Spectra overlay of HSQC NMR spectrum of PH46 (blue) with HSQC (red) and 1H (green) NMR spectra of PH132.
Citation: Zhang T, Scalabrino G, Frankish N, Sheridan H (2018) Bioactive Indanes: Comparative in vitro Metabolism Study of PH46A, a New Potential 
Anti-inflammatory Agent and Biosynthesis of its Primary Metabolite PH132. J Drug Metab Toxicol 9: 239. doi:10.4172/2157-7609.1000239
Page 13 of 14
Volume 9 • Issue 2 • 1000239J Drug Metab Toxicol, an open access journalISSN: 2157-7609
Figure 13a: 1H-1H COSY (upper) NMR spectra of PH132.
Figure 13b ROESY NMR spectra of PH132 (lower).
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